Obesity-Prediabetes Duo: Why Clinicians Must Intervene Early? Written By Dr. Siddhant Milind Dahale4 Feb 2026 12:30 PM ISTPrediabetes is alarmingly common, with the IDF 2025 Atlas estimating nearly 90 million Indians are affected. [1] Escalating obesity,...
SURPASS-2- Tirzepatide vs Semaglutide in Type 2 Diabetes Written By Deeksha Bhandari4 Feb 2026 12:30 PM ISTKey Summary: In addition to meeting the primary objective of noninferiority to semaglutide in type 2 diabetes (T2D), tirzepatide, at a dose of...
Efficacy and Safety of Dapagliflozin-Vildagliptin in Indian T2DM Patients with CV Risk Factors Written By Dr. Nandita Mohan30 Jan 2026 12:58 PM ISTThe Fixed-Dose Combination (FDC) of Dapagliflozin 5 mg + Vildagliptin 50 mg demonstrated significant improvements in Glycemic Control, Metabolic...
SURPASS-2: Superior HbA1c and Weight Reduction With Tirzepatide vs. Semaglutide Written By Deeksha Bhandari29 Jan 2026 11:00 AM ISTThe SURPASS-2 trial compared three doses of tirzepatide (5 mg, 10 mg, 15 mg) with semaglutide 1 mg, in adults with type 2 diabetes who were already...
Regulatory Approval Granted for Reformulated Ranitidine Contributed By Medical Dialogues Team29 Jan 2026 10:00 AM ISTThe U.S. FDA has approved reformulated ranitidine tablets, marking the reintroduction of this widely used H2 receptor antagonist following extensive...
Robust Glycemic Control & Cardio-Renal Protection: Meeting the Advanced Needs of Indian Uncontrolled T2D with Empagliflozin, Sitagliptin, Metformin Written By Dr. Nilanjan Sengupta28 Jan 2026 12:45 PM ISTIndia has an estimated 90 million people living with T2D [1] amid rising obesity and doubled management costs. Uncontrolled T2DM and early-onset...
Evaluation of Biologic Efficacy and Cost per NNT in Moderate-to-Severe Psoriasis: Indian Analysis Written By Medical Dialogues Team22 Jan 2026 10:30 AM ISTEvaluation of Biologic Efficacy and Cost per NNT in Moderate-to-Severe Psoriasis: Indian Analysis. Ixekizumab and ustekinumab were the most...
U.S. FDA Grants Approval for Ranitidine Comeback Written By Medical Dialogues Team20 Jan 2026 10:48 AM ISTDecember 6, 2025: The U.S. Food and Drug Administration (US FDA) in November 2025 has approved reformulated ranitidine tablets, marking the return of...
Dapagliflozin and Sitagliptin FDC in T2D with Heart Failure: 2025 Indian Practice Review Written By Dr. Santosh H.S.17 Jan 2026 11:39 AM ISTAmong India's 89.8 million people with T2D [1], heart failure incidence reaches approximately 50%, with 33% higher hospitalization risk versus...
Importance of Early Aggressive Glucose Control - Approach in 2026 Written By Dr Usha Ayyagari15 Jan 2026 11:15 AM ISTIn this episode of The Diabetes Wellness Forum, titled "Importance of Early Aggressive Glucose Control-Approach in 2026," Dr Nandita Mohan from...
The 1st Tooth Crosstalk | Episode 2 | Brush Early Brush Right - Practical Pearls for Clinicians Written By Dr. Kheya Ghosh Uttam13 Jan 2026 10:58 AM ISTWe bring you Episode 2 of The 1st Tooth Crosstalk: Brush Early Brush Right - Practical Pearls for Clinicians.In this episode, we are joined by two...
FOGSI Expert Consensus Review Redefines Landscape of Endometriosis Management with Elagolix: 5 Key Takeaways Written By Swapnil Sharma12 Jan 2026 11:30 AM ISTEndometriosis is a chronic, estrogen-dependent condition affecting an estimated 10% of women of reproductive age worldwide and is a leading cause of...
